Growth inhibition in human breast cancer cells with the combination of a PKC inhibitor and zoledronic acid.

被引：0
|
作者：
Witters, LM
Green, J
Seaman, J
Lipton, A
Milton, S
机构：
[1] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
675
引用
收藏
页码：S166 / S166
页数：1
相关论文
共 50 条
  • [1] Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines
    Witters, LM
    Crispino, J
    Fraterrigo, T
    Green, J
    Lipton, A
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : S92 - S97
  • [2] Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro
    Han Qiao
    Ting-yu Wang
    Wei Yan
    An Qin
    Qi-ming Fan
    Xiu-guo Han
    Yu-gang Wang
    Ting-ting Tang
    [J]. Acta Pharmacologica Sinica, 2015, 36 : 1085 - 1098
  • [3] Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro
    Qiao, Han
    Wang, Ting-yu
    Yan, Wei
    Qin, An
    Fan, Qi-ming
    Han, Xiu-guo
    Wang, Yu-gang
    Tang, Ting-ting
    [J]. ACTA PHARMACOLOGICA SINICA, 2015, 36 (09) : 1085 - 1098
  • [4] Targeting a breast cancer xenograft by modulation of the microenvironment with zoledronic acid.
    Nienhuis, Hilde H.
    Arjaans, Marlous
    Timmer-Bosscha, Hetty
    de Vries, Elisabeth G. E.
    Schroder, Carolina P.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [5] Author Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro
    Han Qiao
    Ting-yu Wang
    Wei Yan
    An Qin
    Qi-ming Fan
    Xiu-guo Han
    Yu-gang Wang
    Ting-ting Tang
    [J]. Acta Pharmacologica Sinica, 2019, 40 : 1127 - 1128
  • [6] The motility of cultured breast cancer stem-like cells is severely restricted by zoledronic acid.
    Hoberg, C.
    Nguemgo-Kouam, P.
    Kochanneck, A.
    Fakhrian, K.
    Buehler, H.
    Adamietz, I.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 120 - 120
  • [7] Inhibition of growth of human breast cancer cell lines with the combination of an mTOR inhibitor and a Bcl-2 inhibitor
    Wilson, Matthew
    Witters, Lois
    Lane, Heidi
    Lipton, Allan
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [8] Inhibition of breast cancer growth with the combination of lapatinib and an ADAM protease inhibitor
    Witters, L. M.
    Scherle, P. A.
    Friedman, S. M.
    Redman, J.
    Fridman, J. S.
    Caulder, E.
    Lipton, A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S82 - S82
  • [9] A cathepsin K inhibitor (alone or in combination with zoledronic acid) inhibits the progression of breast cancer bone metastases
    Le Gall, C
    Guglielmi, J
    Gasser, J
    Zimmermann, J
    Clézardin, P
    [J]. BONE, 2006, 38 (03) : S55 - S56
  • [10] Zoledronic acid mediates ras-independent growth inhibition of prostate cancer cells
    Nogawa, M
    Yuasa, T
    Kimura, S
    Kuroda, J
    Segawa, H
    Sato, K
    Yokota, A
    Koizumi, M
    Maekawa, T
    [J]. ONCOLOGY RESEARCH, 2005, 15 (01) : 1 - 9
12345